AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Status:
Recruiting
Trial end date:
2030-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well azacitidine and venetoclax work in treating patients
with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as
azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.